In recent years, the persistently high prices of imported originator drugs have drawn widespread public concern. Originator drugs refer to innovative medicines initially developed by multinational pharmaceutical companies and protected by patents. During the patent period, these companies enjoy market exclusivity and can set their own prices. Thus, high prices are often not the result of ‘speculation’ by middlemen, but stem from pricing strategies based on R&D costs, global market considerations, and international pricing systems.That said, the distribution chain also contributes to inflated costs. Imported drugs may pass through multiple layers of agents, customs clearance, warehousing, and logistics, each adding a markup. In regions with limited health insurance coverage, high out-of-pocket expenses further amplify patients’ perception of drug costs. Additionally, lack of price transparency and insufficient market competition can be exploited by certain channels to create artificial scarcity, indirectly driving up prices.Notably, China has significantly reduced prices for some originator drugs in recent years through national bulk procurement programs, accelerated generic drug quality evaluations, and streamlined import approval processes. Going forward, strengthening price regulation, enhancing negotiation power, and expanding insurance coverage will be key to curbing unreasonable drug pricing.In short, the high cost of imported originator drugs primarily results from patent monopolies and global pricing mechanisms—not mere ‘speculation.’ The solution lies in systemic reforms and market optimization, not just blaming the distribution chain.
近年来，进口原研药价格居高不下，引发公众广泛关注。所谓‘原研药’，是指由跨国制药企业首次研发并拥有专利保护的创新药物。在专利期内，这些企业享有市场独占权，可自主定价。因此，部分高价并非由中间商‘炒作’所致，而是源于原研药企基于研发成本、市场策略及国际定价体系制定的价格。然而，流通环节也存在推高药价的因素。例如，部分进口药需经多级代理、报关、仓储和配送，层层加价；某些地区医保覆盖不足，患者自费比例高，进一步放大价格感知。此外，信息不透明和市场竞争不充分也可能被个别渠道利用，制造‘稀缺’假象，间接抬价。值得注意的是，中国近年通过国家药品集中带量采购、加快仿制药一致性评价、优化进口审批流程等措施，已显著降低部分原研药价格。未来，加强价格监管、提升谈判能力、扩大医保目录，将是遏制不合理药价的关键路径。简言之，进口原研药高价主因在于专利垄断与全球定价机制，而非单纯‘炒作’。解决之道在于制度优化与市场改革，而非仅归咎于流通环节。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/7646.html